\
&
Contact us
\
&
Contact us
Published on | 1 year ago
Programmes Horizon Europe HorizonEU L+FThe personnel cost of SME owners and natural person beneficiaries has to be declared by using the unit cost (daily rate) fixed by the authorising decision C(2020)71155 and set out in Annex 2a, as explained in the Annotated Model Grant Agreement p. 64.
This Annex 2a has been updated on 01/08/202: for calls with opening date as from 30 July 2024 the daily rate has been changed to EUR 8 745,40 / 18 days = 485,85 multiplied by the country-specific correction coefficien of the country where the beneficiary is etablished; if Belgium, then this coëfficient is 1.
For calls with opening date before 30 July 2024, this daily rate remains EUR 5 080 / 18 days = 282,22 multiplied by the country-specific correction coefficient of the country where the beneficiary is etablished; if Belgium, then this coëfficient is 1.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Deployment: Best use of technologies
Please note that the European Commission has extended the deadline for call DIGITAL-2025-BESTUSE-TECH-09 with the following two call topics: European Digital Identity Wallet EU Mobile Driving Licences) NEW closing date: 15 January 2026 (previously 09 December 2025) read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
